Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review

Background: There is growing consensus that neurologists should consider disease-modifying therapies early in multiple sclerosis (MS). However, there is a subgroup with a natural benign course, in which treatment could be postponed. We sought to determine the frequency of benign MS and early clinical factors that may predict a benign course. Methods: We performed a systematic review of the existing literature on benign MS, which was defined as minimal or no disability equivalent to a score on the Expanded Disability Status Scale (EDSS) 43.0 at least 10 years after disease onset. Results: Only a small number of studies of adequate quality was available. In total there were nine published studies representing 2204 patients. The estimated frequency of benign MS was 26.7%. Onset with optic neuritis, onset before the age of 40 years, absence of pyramidal signs at presentation, duration of first remission more than 1 year, and only one exacerbation in the first 5 years after onset of MS, were associated with a benign course. Conclusions: From the existing literature a set of unrelated clinical characteristics emerged that was associated with a benign course of MS. However, there is a need for prospective studies to define more precisely clinical and paraclinical predictors of benign MS.

[1]  A. Thompson,et al.  A clinical and laboratory study of benign multiple sclerosis. , 1986, The Quarterly journal of medicine.

[2]  J. G. Phadke Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. , 1990, Brain : a journal of neurology.

[3]  G V McDonnell,et al.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.

[4]  G. Aimard,et al.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. , 1980, Brain : a journal of neurology.

[5]  A J Thompson,et al.  Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. , 1999, Neurology.

[6]  R. Rudick Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. , 1999, Archives of neurology.

[7]  B. Weinshenker,et al.  The natural history of multiple sclerosis. , 1995, Neurologic clinics.

[8]  K. Lauer,et al.  Epidemiological investigations into multiple sclerosis in Southern Hesse. V. Course and prognosis , 1987, Acta neurologica Scandinavica.

[9]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[10]  B. Ryberg Antibrain antibodies in multiple sclerosis Relation to clinical variables , 1982, Journal of the Neurological Sciences.

[11]  D. Mcalpine The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. , 1961, Brain : a journal of neurology.

[12]  G. Beebe,et al.  Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. , 1977, Journal of chronic diseases.

[13]  M. Alter,et al.  CLINICAL FACTORS ASSOCIATED WITH INCREASED DISABILITY IN MULTIPLE SCLEROSIS , 1970, Acta neurologica Scandinavica.

[14]  G J Barker,et al.  Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? , 1999, Journal of neurology, neurosurgery, and psychiatry.

[15]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[16]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.